These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18236984)

  • 41. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
    Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
    J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perindopril for improving cardiovascular events.
    DiNicolantonio JJ; O'Keefe JH
    Vasc Health Risk Manag; 2014; 10():539-48. PubMed ID: 25210459
    [No Abstract]   [Full Text] [Related]  

  • 43. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renin-angiotensin system blockade and cardiovascular and renal protection.
    Hoogwerf BJ
    Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Telmisartan, ramipril, or both in patients at high risk of vascular events.
    Büchner N; Banas B; Krämer BK
    N Engl J Med; 2008 Jul; 359(4):426. PubMed ID: 18650521
    [No Abstract]   [Full Text] [Related]  

  • 46. Hypertension treatment and implications of recent cardiovascular outcome trials.
    Weber MA
    J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
    Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
    Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.
    Böhm M; Schumacher H; Leong D; Mancia G; Unger T; Schmieder R; Custodis F; Diener HC; Laufs U; Lonn E; Sliwa K; Teo K; Fagard R; Redon J; Sleight P; Anderson C; O'Donnell M; Yusuf S
    Hypertension; 2015 Mar; 65(3):651-61. PubMed ID: 25583157
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Telmisartan in high-risk cardiovascular patients.
    Weber MA
    Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rationale for double renin-angiotensin-aldosterone system blockade.
    Unger T; Stoppelhaar M
    Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Angiotensin-receptor blockers in prevention of cardiovascular events: are they as effective as angiotensin-converting enzyme inhibitors?
    Teo KK
    Pol Arch Med Wewn; 2009; 119(1-2):8-10. PubMed ID: 19341172
    [No Abstract]   [Full Text] [Related]  

  • 53. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.
    Probstfield J
    J Fam Pract; 2009 Jun; 58(6 Suppl):S1-8. PubMed ID: 19508849
    [No Abstract]   [Full Text] [Related]  

  • 54. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials.
    Gosse P; Neutel JM; Schumacher H; Lacourcière Y; Williams B; Davidai G
    Blood Press Monit; 2007 Jun; 12(3):141-7. PubMed ID: 17496463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benefits and risks of combination therapy in hypertension.
    Node K
    Hypertens Res; 2009 Sep; 32(9):727-8. PubMed ID: 19609269
    [No Abstract]   [Full Text] [Related]  

  • 56. More hype than HOPE.
    Moutsatsos GD
    Hypertension; 2003 Apr; 41(4):e4; author reply e5. PubMed ID: 12623866
    [No Abstract]   [Full Text] [Related]  

  • 57. ONTARGET should not be over interpreted.
    Abutaleb N
    Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
    [No Abstract]   [Full Text] [Related]  

  • 58. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
    Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
    Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Proteinuria: Is the ONTARGET renal substudy actually off target?
    Ruggenenti P; Remuzzi G
    Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
    [No Abstract]   [Full Text] [Related]  

  • 60. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
    Mancia G; Schumacher H; Redon J; Verdecchia P; Schmieder R; Jennings G; Yusoff K; Ryden L; Liu GL; Teo K; Sleight P; Yusuf S
    Circulation; 2011 Oct; 124(16):1727-36. PubMed ID: 21947289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.